Secondary Logo

Journal Logo

May 1996 - Volume 5 - Issue 5
pp: 313-390

PDF Only


TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL;

Froon, Albert M.F.; Greve, Jan Willem M.; Buurman, Wim A.; More

Shock. 5(5):313-319, May 1996.


PDF Only